- Home
- ACIC vs VSTM Comparison
ACIC vs VSTM Comparison
Compare ACIC & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- VSTM
- Stock Information
- Founded
- ACIC 1999
- VSTM 2010
- Country
- ACIC United States
- VSTM United States
- Employees
- ACIC N/A
- VSTM N/A
- Industry
- ACIC Property-Casualty Insurers
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- ACIC Finance
- VSTM Health Care
- Exchange
- ACIC Nasdaq
- VSTM Nasdaq
- Market Cap
- ACIC 556.0M
- VSTM 531.1M
- IPO Year
- ACIC N/A
- VSTM 2012
- Fundamental
- Price
- ACIC $11.05
- VSTM $9.25
- Analyst Decision
- ACIC Buy
- VSTM Strong Buy
- Analyst Count
- ACIC 1
- VSTM 8
- Target Price
- ACIC $16.00
- VSTM $12.43
- AVG Volume (30 Days)
- ACIC 221.3K
- VSTM 2.9M
- Earning Date
- ACIC 08-06-2025
- VSTM 08-07-2025
- Dividend Yield
- ACIC 4.55%
- VSTM N/A
- EPS Growth
- ACIC 14.01
- VSTM N/A
- EPS
- ACIC 1.63
- VSTM N/A
- Revenue
- ACIC $320,072,000.00
- VSTM $2,137,000.00
- Revenue This Year
- ACIC $4.91
- VSTM $86.06
- Revenue Next Year
- ACIC $4.16
- VSTM $395.22
- P/E Ratio
- ACIC $6.74
- VSTM N/A
- Revenue Growth
- ACIC 33.90
- VSTM N/A
- 52 Week Low
- ACIC $8.82
- VSTM $2.34
- 52 Week High
- ACIC $15.08
- VSTM $9.43
- Technical
- Relative Strength Index (RSI)
- ACIC 56.87
- VSTM 73.31
- Support Level
- ACIC $10.31
- VSTM $8.71
- Resistance Level
- ACIC $11.22
- VSTM $9.43
- Average True Range (ATR)
- ACIC 0.30
- VSTM 0.61
- MACD
- ACIC 0.02
- VSTM 0.08
- Stochastic Oscillator
- ACIC 81.32
- VSTM 90.95
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.